Dr. Reddy's Lab launches trastuzumab biosimilar in domestic market

The drug is a biosimilar indicated for the treatment of HER2-positive cancers including early breast cancer, metastatic breast cancer and metastatic gastric cancer.

Dr. Reddy's Hervycta (trastuzumab), a biosimilar of Roche's Herceptin, is available in 150mg and 440mg multiple dose vials. The company has commercialized four biosimilar products in India and other emerging markets. Dr. Reddy's active pipeline includes several biosimilar products in the oncology and immunology segment.

Herceptin, marketed under the brand name Herdon in India, and its biosimilars had sales of approximately Rs. 290 crore MAT in India, for the calender year 2017, reported Ipsos India.

Ahead of its results announcement, at 11:03 hours, the stock of Dr. Reddy's Laboratories was quoting Rs. 2,113.50 per share, up by Rs. 24.50 or 1.17 per cent on Thursday. While the benchmark indices were trading at their new highs, BSE Sensex was at S&P BSE Sensex was at 37,019.30, up by 161.07 points or 0.44 per cent, and Nifty50 was at 11,176.60, up by 44.60 or 0.40 per cent.